Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
COR 
Cencora Inc. (COR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: COR (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $334
1 Year Target Price $334
| 10 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 49.06% | Avg. Invested days 63 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 64.13B USD | Price to earnings Ratio 34 | 1Y Target Price 334 |
Price to earnings Ratio 34 | 1Y Target Price 334 | ||
Volume (30-day avg) 17 | Beta 0.63 | 52 Weeks Range 222.57 - 331.94 | Updated Date 10/23/2025 |
52 Weeks Range 222.57 - 331.94 | Updated Date 10/23/2025 | ||
Dividends yield (FY) 0.66% | Basic EPS (TTM) 9.73 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.6% | Operating Margin (TTM) 1.22% |
Management Effectiveness
Return on Assets (TTM) 3.1% | Return on Equity (TTM) 116.71% |
Valuation
Trailing PE 34 | Forward PE 17.64 | Enterprise Value 65833531740 | Price to Sales(TTM) 0.2 |
Enterprise Value 65833531740 | Price to Sales(TTM) 0.2 | ||
Enterprise Value to Revenue 0.21 | Enterprise Value to EBITDA 16.38 | Shares Outstanding 193877881 | Shares Floating 185608989 |
Shares Outstanding 193877881 | Shares Floating 185608989 | ||
Percent Insiders 4.2 | Percent Institutions 93.9 |
Upturn AI SWOT
Cencora Inc.
Company Overview
History and Background
Cencora Inc., formerly AmerisourceBergen, was founded in 2001 through the merger of Bergen Brunswig and AmeriSource Health Corporation. The company has grown through acquisitions and organic expansion, evolving into a global healthcare solutions provider.
Core Business Areas
- U.S. Healthcare Solutions: Distributes pharmaceuticals and healthcare products, provides specialty pharmacy services, and offers value-added solutions to healthcare providers and manufacturers in the United States.
- International Healthcare Solutions: Distributes pharmaceuticals and healthcare products and provides related services outside of the United States, primarily in Europe and Canada.
Leadership and Structure
Steven H. Collis serves as the Chairman, President, and CEO. The company operates with a functional organizational structure, including departments for finance, operations, sales, and marketing.
Top Products and Market Share
Key Offerings
- Competitors: McKesson, Cardinal Health
- Market Share (%): Estimated ~25-30% (aggregate, exact figures not publicly available)
- Pharmaceutical Distribution: Core offering involving the distribution of branded and generic pharmaceuticals to pharmacies, hospitals, and other healthcare providers. They hold a significant portion of the market. Competitors include McKesson and Cardinal Health.
- Competitors: CVS Health, OptumRx
- Market Share (%): Estimated ~15-20% (aggregate, exact figures not publicly available)
- Specialty Pharmacy Services: Provides services for managing and dispensing specialty medications, which are often high-cost and require special handling. This includes services for oncology, autoimmune, and other complex conditions. Competitors include CVS Health and OptumRx.
Market Dynamics
Industry Overview
The pharmaceutical distribution industry is characterized by high regulation, consolidation, and reliance on strong relationships with manufacturers and pharmacies. Growth is driven by increasing healthcare spending, aging populations, and the development of new drugs.
Positioning
Cencora Inc. is one of the top three pharmaceutical distributors in the United States, possessing significant scale, established distribution networks, and long-standing relationships with key stakeholders. They are focused on expanding their specialty pharmacy services and international presence.
Total Addressable Market (TAM)
The global pharmaceutical distribution market is estimated to be worth hundreds of billions of dollars. Cencora Inc. is well-positioned to capture a significant portion of this market due to its size and capabilities.
Upturn SWOT Analysis
Strengths
- Large scale and market share
- Established distribution network
- Strong relationships with manufacturers and pharmacies
- Growing specialty pharmacy business
- International presence
Weaknesses
- Reliance on a few large customers
- Exposure to regulatory changes
- Pricing pressure from manufacturers and payers
- Litigation risks associated with opioid distribution
- High debt levels
Opportunities
- Expanding into new markets
- Acquiring smaller distributors
- Developing new value-added services
- Leveraging data and analytics
- Capitalizing on the growth of biosimilars
Threats
- Increased competition
- Generic drug price deflation
- Changes in reimbursement policies
- Supply chain disruptions
- Product recalls
Competitors and Market Share
Key Competitors
- McKesson (MCK)
- Cardinal Health (CAH)
Competitive Landscape
Cencora Inc. competes with McKesson and Cardinal Health based on price, service, and product offerings. Cencora Inc. has advantages in certain specialty areas and international markets, while facing challenges from aggressive pricing strategies.
Major Acquisitions
PharMEDium
- Year: 2015
- Acquisition Price (USD millions): 2575
- Strategic Rationale: Expanded Cencora Inc.'s presence in the sterile compounding market.
Growth Trajectory and Initiatives
Historical Growth: Cencora Inc. has experienced consistent growth through organic expansion and strategic acquisitions.
Future Projections: Analysts project continued growth in revenue and earnings, driven by increasing demand for pharmaceuticals and healthcare services.
Recent Initiatives: Recent initiatives include expanding specialty pharmacy services, investing in technology, and pursuing strategic acquisitions.
Summary
Cencora Inc. is a major player in the pharmaceutical distribution industry, benefiting from its scale and established relationships. While facing competition and regulatory headwinds, the company is well-positioned to capitalize on the growing demand for healthcare services. Growth can be achieved through strategic acquisition and expansion into new markets but it needs to monitor debt levels and competitive pressures. The company is doing well, especially in specialty pharmacies, but should cautiously navigate opioid litigation and reimbursement shifts.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q), Investor Presentations, Market Research Reports, Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cencora Inc.
Exchange NYSE | Headquaters Conshohocken, PA, United States | ||
IPO Launch date 1995-04-04 | President, CEO & Director Dr. Robert P. Mauch Ph.D., PharmD | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 51000 | Website https://www.cencora.com |
Full time employees 51000 | Website https://www.cencora.com | ||
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.